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Abstract River blindness, caused by infection with the fi-
larial nematode Onchocerca volvulus, is a neglected tropi-
cal disease affecting millions of people. There is a clear
need for diagnostic tools capable of identifying infected
patients, but that can also be used for monitoring disease
progression and treatment efficacy. Plasma-derived para-
sitic microRNAs have been suggested as potential candi-
dates for such diagnostic tools. We have investigated
whether these parasitic microRNAs are present in suffi-
cient quantity in plasma of Onchocerca-infected patients
to be used as a diagnostic biomarker for detection of
O. volvulus infection or treatment monitoring. Plasma sam-
ples were collected from different sources (23 nodule-
positive individuals and 20 microfilaridermic individuals),
microRNAs (miRNAs) were extracted using Qiagen
miRNeasy kit, and a set of 17 parasitic miRNAs was eval-
uated on these miRNA extracts using miRCURY Locked
Nucleic Acid (LNA) Universal RT microRNA PCR sys-
tem. Of the 17 miRNAs evaluated, only 7 miRNAs were
found to show detectable signal in a number of samples:
bma-miR-236-1, bma-miR-71, ov-miR71-22nt, ov-miR-
71-23nt, ov-miR-100d, ov-bantam-a, and ov-miR-87-3p.
Subsequent melting curve analysis, however, indicated that
the signals observed for ov-miR-71 variants and ov-miR-
87-3p are non-specific. The other miRNAs only showed
positive signal in one or few samples with Cq values just
below the cutoff. Our data indicate that parasitic miRNAs
are not present in circulation at a sufficiently high level to
be used as biomarker for O. volvulus infection or treatment
monitoring using LNA-based RT-qPCR analysis.
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Introduction
Onchocerciasis, a neglected tropical disease commonly
known as river blindness, is caused by infection with the fi-
larial nematode,Onchocerca volvulus (O. volvulus). In Africa,
at least 120 million people are at risk of infection (Borup et al.
2003; Enk 2006). The last comprehensive survey conducted
in 2008 indicated that 26 million people were infected with
Onchocerca, of whom 265,000 were blind and 746,000 were
visually impaired. In addition, approximately 4 million people
suffer from onchodermatitis with severe itching (WHO 2010).
Since 1987, ivermectin has been used in mass drug adminis-
tration (MDA) programs to treat hundreds of millions of peo-
ple resulting in a reduction of both visual impairment and
symptomatic onchodermatitis (Cupp et al. 2011).
Besides clinical examination by palpation of nodules formed
by adult worms (macrofilariae), diagnostic tools for detection of
O. volvulus infection traditionally were limited to detection of
microfilariae (mf) in small, superficial skin biopsy samples (so-
called skin snips) (Taylor et al. 1989). More recent research,
however, also resulted in the development of rapid-format tests
for the detection of IgG4 antibodies to the parasitic antigen Ov-
16 (Chandrashekar et al. 1996; Golden et al. 2013; Lavebratt
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et al. 1994; Lipner et al. 2006; Steel et al. 2015; Weil et al.
2000). This test is predominantly useful in a surveillance setting
where it can be used for the identification of incident infections
in communities having already undergone MDA (Golden et al.
2013). Diagnostic tests that can distinguish between past and
active infection or that can be used for monitoring disease pro-
gression or treatment response are currently still lacking.
Several efforts have therefore been undertaken to identify novel
biomarkers that hold potential to be used in such diagnostic
tests (Vlaminck et al. 2015). For Dirofilaria immitis
(heartworm) and Wuchereria bancrofti (the most prevalent
cause of lymphatic filariasis), this has been successful as sensi-
tive assays have been developed that detect circulating filarial
antigens in the blood (More and Copeman 1990; Weil 1987;
Weil et al. 2013; Weil et al. 1997). An approach that has shown
promise is the use of metabolome analysis of serum or urine
samples from infected individuals, which has led to the identi-
fication of urinary N-acetyltyramine-O,β-glucuronide
(NATOG) as a unique biomarker for O. volvulus infection
(Denery et al. 2010; Globisch et al. 2013; Lagatie et al. 2016).
Recent deep sequencing work has revealed the presence of
many microRNA (miRNA) homologues in nematode para-
sites. Studies on whole worm extracts have identified
miRNAs produced by Brugia malayi (Poole et al. 2010;
Poole et al. 2014) andD. immitis (Fu et al. 2013). Other works
suggest that these parasite miRNAs may play a role in adap-
tation to life in the vertebrate host (Britton et al. 2014) and
possibly also modulate the innate immunity of the host (Buck
et al. 2014). Indeed, deep sequencing studies identified several
parasitic miRNAs in host circulation upon infection with Loa
loa (Tritten et al. 2014b), Onchocerca ochengi (Tritten et al.
2014b), Litomosoides sigmodontis (Buck et al. 2014),
Schistosoma mansoni (Hoy et al. 2014), D. immitis (Tritten
et al. 2014a), and O. volvulus (Quintana et al. 2015; Tritten
et al. 2014a).
O. volvulus miRNAs have been detected in serum of in-
fected individuals (Quintana et al. 2015). Of the six different
miRNAs detected (miR-71, lin-4, miR-100d, miR-87-3p, mir-
100a, and bantam-a), only miR-71 and lin-4 were found both
in samples of patients from Cameroon and in samples of pa-
tients from Ghana. MiR-87-3p and miR-100a were only de-
tected in samples of Ghanaian patients. The other two
miRNAs (miR100d and bantam-a) were found both in infect-
ed and uninfected patients from Ghana. This work was per-
formed only with pooled serum using small RNA sequencing
on the Illumina platform. No information was collected on the
detection frequency of these miRNAs in serum of infected
individuals, nor on the levels in individual samples. Also, no
confirmation of these findings using standard PCR technology
has been performed. Therefore, we wanted to determine the
levels of several (putative) O. volvulus miRNAs in different




The following material was obtained through the Filariasis
Research Reagent Resource Center (FR3), Division of
Microbiology and Infectious Diseases, NIAID, NIH: a set of
20 O. volvulus-infected human serum samples, from Dr.
Nutman, collected in Cameroon. All samples were de-
identified before they were provided to FR3, and usage of these
samples for research purposes was approved by the Smith
College Institutional Review Board (IRB). Information on
O. volvulus infection (number of microfilaria/mg skin and num-
ber of palpable nodules) was provided by FR3, along with
demographic information (Table 1). All infected individuals
had at least two palpable nodules and 25 mf/mg skin
(microfilaridermia) as determined by skin snip. Sera were col-
lected from clotted blood obtained by venipuncture. The nega-
tive panel was composed of eight serum samples from healthy,
non-infected individuals from Southern Africa, was collected in
FDA-regulated donor centers in the USA, and was provided by
Tissue Solutions Ltd. (Glasgow, Scotland). Written informed
consent was obtained from all individuals, and all samples were
decoded and de-identified before they were provided for re-
search purposes. Demographic information was also provided
(Table 1). All samples were stored at −80 °C until analysis.
A second set of EDTA plasma samples was collected as part
of a field study in Ghana. This study was undertaken in an
onchocerciasis-endemic community located in Adansi South
District along the Pra River basins in the Ashanti Region of
Ghana. This study was approved by the Committee on
Human Research Publications and Ethics of the School of
Medical Sciences of the Kwame Nkrumah University of
Science and Technology, Kumasi, Ghana, and study subjects
signed an informed consent form. Physical examinations were
performed to identify those subjects having palpable nodules.
Skin snips (biopsies) were then taken from those with nodules
in order to determine the microfilarial (mf) load in the skin
(Debrah et al. 2015). Most subjects were participating in
MDA programs. A total of 23 nodule-positive subjects that
donated plasma samples were included. Additionally, EDTA
plasma samples from six non-endemic controls (from
Kumasi, Ashanti Region) were included. An overview of the
patient demographics is also provided in Table 1. All samples
were stored at −80 °C until analysis.
Synthetic microRNAmolecules and generation of miRNA
standard curves
Six RNase-free 5′-phosphorylated miRNA oligoribonucleotides
were synthesized (Integrated DNATechnologies) for the valida-
tion of the miRNA assays, corresponding to bma-miR-71, ov-
miR-71 22nt, ov-miR-71 23nt, ov-miR-87-3p, hsa-miR-425-5p,
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Table 1 Demographic







852-005 Ghana Nod. 54 M 0 2 − KCCR
854-036 Ghana Nod. 62 M 0 1 + KCCR
853-043 Ghana Nod. 74 M 0 1 + KCCR
855-037 Ghana Nod. 55 M 0 2 − KCCR
850-011 Ghana Nod. 21 F 0 2 + KCCR
850-034 Ghana Nod. 22 M 0 1 − KCCR
852-025 Ghana Nod. 28 F 0 1 − KCCR
852-046 Ghana Nod. 25 F 0 1 + KCCR
854-009 Ghana Nod. 58 M 0 1 + KCCR
851-033 Ghana Nod. 30 M 0 1 + KCCR
855-040 Ghana Nod. 50 F 0 3 + KCCR
853-060 Ghana Nod. 44 M 0 2 + KCCR
854-030 Ghana Nod. 40 F 0 2 − KCCR
850-052 Ghana Nod. 29 F 0 1 + KCCR
856-020 Ghana Nod. 52 M 0 5 + KCCR
851-014 Ghana Nod. 58 M 0 2 + KCCR
853-051 Ghana Nod. 58 F 0 1 − KCCR
852-028 Ghana Nod. 80 F 0 1 + KCCR
852-038 Ghana Nod. 21 M 0 1 − KCCR
854-031 Ghana Nod. 60 F 0 1 + KCCR
854-043 Ghana Nod. 67 M 0.6 4 + KCCR
853-014 Ghana Nod. 21 M 0 1 + KCCR
850-072 Ghana Nod. 28 M 0 1 + KCCR
500-501 Ghana NEC 26 M 0 0 − KCCR
500-503 Ghana NEC 25 F 0 0 − KCCR
500-504 Ghana NEC 43 M 0 0 − KCCR
500-505 Ghana NEC 26 M 0 0 − KCCR
500-506 Ghana NEC 28 F 0 0 − KCCR
500-507 Ghana NEC 28 M 0 0 − KCCR
MC 179 Cameroon mf 47 M 100 7 + FR3
MC 202 Cameroon mf 52 M 89 9 + FR3
MC 211 Cameroon mf 54 F 36 2 + FR3
MC 215 Cameroon mf 55 F 45 2 − FR3
MC 224 Cameroon mf 60 F 26 3 + FR3
MC 226 Cameroon mf 75 F 99 7 + FR3
MC 234 Cameroon mf 50 F 70 2 + FR3
MC 253 Cameroon mf 54 M 40 6 + FR3
MC 260 Cameroon mf 39 F 26 2 + FR3
MC 319 Cameroon mf 60 M 40 2 + FR3
MC 326 Cameroon mf 46 M 45 2 + FR3
MC 328 Cameroon mf 37 M 74 6 + FR3
MC 331 Cameroon mf 54 M 78 5 + FR3
MC 333 Cameroon mf 43 M 300 6 + FR3
MC 335 Cameroon mf 23 M 30 4 + FR3
MC 341 Cameroon mf 22 M 52 5 + FR3
MC 343 Cameroon mf 35 M 200 2 − FR3
MC 352 Cameroon mf 60 M 200 14 + FR3
MC 360 Cameroon mf 66 F 98 6 + FR3
MC 362 Cameroon mf 70 F 26 6 + FR3
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and hsa-miR-93-5p. Stock solutions of 100 μM synthetic oligo-
nucleotide in RNase-free and DNase-free water were prepared
according to the quantities quoted by the manufacturer (based on
spectrophotometric analysis). Tenfold dilution series were pre-
pared in RNase-free and DNase-free water, starting at 108
copies/μL down to 102 copies/μL. These samples and no tem-
plate control (NTC; zero copies) were further processed and
analyzed similar to the study samples.
miRNA analysis by miRCURY LNA Universal RT
miRNA PCR
RNAwas purified from 25 or 200 μL serum/plasma, as indi-
cated, with the miRNeasy kit from Qiagen (Venlo, Holland)
according to the manufacturers’ protocol. Reverse transcrip-
tion reactions were performed using the miRCURY LNA
Universal RT MicroRNA PCR Universal complementary
DNA (cDNA) kit II (Exiqon, Vedbaek, Denmark). Reverse
transcription thermocycling parameters were as follows:
42 °C for 60 min and 95 °C for 5 min. qPCR was performed
using the miRCURY LNA Universal RT microRNA PCR
system (Exiqon, Vedbaek, Denmark) with 17 parasitic
miRNAs and 2 human miRNAs as internal control. All
primer/probe sets for parasitic miRNAs were custom designed
by the supplier. Also, three extraction controls and two cDNA
synthesis controls were used as indicated by the provider. All
miRNAs analyzed are listed in Table 2. Two real-time qPCR
amplifications were performed for each RT reaction.
Reactions were performed according to the manufacturers’
instructions using a LightCycler 480 system (Roche). qPCR
thermocycling conditions were as follows: 95 °C for 10 min,
followed by 45 cycles of 95 °C for 10 s and 60 °C for 1 min.
Melt curve analysis was performed between 60 and 95 °C at a
ramp rate of 0.11 °C/s. Detectable miRNAs were those with a
Cq (quantification cycle) <40.0 in one of both duplicates. An
overview of the different sample volumes used for extraction,
RNA volumes used for cDNA synthesis, and the different
cDNA dilutions used for qPCR is presented in Table 3.
Statistical analysis
Results of internal and external controls (extraction controls,
cDNA synthesis controls, and human referencemiRNAs) were
used as quality control of the samples evaluated. Results of
these controls were subjected to outlier testing in order to iden-
tify samples with poor extraction and/or cDNA synthesis effi-
ciency. For each control assay, all samples analyzed under the
same conditions (i.e., same input volume and cDNA dilution)
were subjected to outlier detection with a Grubbs’ test (using a
significance level of 0.05) using the GraphPad online outlier
calculator (http://graphpad.com/quickcalcs/Grubbs1.cfm)
(Grubbs 1969). In case an outlier was detected, sample was
not included for further analysis. This process of outlier iden-
tification was iterated until no outliers were detected. For com-
parison of Tm values in different groups, two-tailed unpaired t
test was performed using the GraphPad Prism version 6.02. P
value <0.05 was considered to be significantly different.
Results
Assay validation: standard curves and cutoff
determination
In order to confirm the performance of the miRCURY LNA
Universal RT microRNA PCR system, dilution curves were
Table 1 (continued)









HC 17 F 0 0 − TS
Ab-E11962 Southern
Africa
HC 17 M 0 0 − TS
Ab-E11968 Southern
Africa
HC 17 F 0 0 − TS
Ab-E11969 Southern
Africa
HC 17 F 0 0 − TS
Ab-E11970 Southern
Africa
HC 17 F 0 0 − TS
Ab-E12152 Southern
Africa
HC 25 M 0 0 − TS
Ab-E12153 Southern
Africa
HC 33 M 0 0 − TS
Ab-E12160 Southern
Africa
HC 47 M 0 0 − TS
Nod., nodule positive, NEC non-endemic control, mf microfilaridermic, HC healthy control, KCCR Kumasi
Centre for Collaborative Research, FR3 Filariasis Research Reagent Resource Center, TS Tissue Solutions, Ltd.
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prepared for four parasitic miRNAs (bma-miR-71, ov-miR-71
22nt, ov-miR-71 23nt, and ov-miR-87-3p) and two human
reference miRNAs (hsa-miR-425-5p and hsa-miR-93-5p).
Each dilution curve was analyzed in duplicate using its respec-
tive assay, and resulting Cq values were used to generate stan-
dard curves (Fig. 1). All tested assays had good linearity
(r2 > 0.98) and acceptable PCR efficiency (slope was between
−3.12 and −3.89, corresponding to PCR efficiencies between
80.8 and 109%). The lowest concentration used for each
miRNA, 28 copies/reaction (1.45 log copies/reaction), was
well detectable in all assays. The average Cq value for the
four O. volvulus miRNAs at this concentration, being 35.9,
was therefore chosen as cutoff for positivity in all miRNA
assays used in this work. This cutoff approximates the cutoff
of 37, recommended by the supplier. Based on this cutoff, for
each experimental setup, a limit of detection (number of
copies/μL plasma) was calculated and ranged between 0.85
and 2.46 log copies/μL plasma (Table 3).
Determination of plasma levels of parasitic miRNAs
in samples from nodule-positive subjects
Based on the information that has been published before, a list
of 17 parasitic miRNAs was compiled (Buck et al. 2014;
Table 3 Variable RNA input and
cDNA dilutions used for different
sample sets
Sample set Sample input (μL) RNA input (μL) cDNA dilution LODa (log copies/μL plasma)
KCCR 200 5 1/50 1.64
KCCR 200 5 1/8 0.85
FR3 + TS 25 6 1/50 2.46
KCCR Kumasi Centre for Collaborative Research, FR3 Filariasis Research Reagent Resource Center, TS Tissue
Solutions, Ltd.
a Based on 28 copies/qPCR reaction and 100% extraction and cDNA synthesis efficiency
Table 2 miRNAs analyzed in this study
miRNA Sequence Remark Ref.
bma-miR-36a TCACCGGGTGCACATTCGGTC Female specific Poole et al. (2014)
bma-miR-84 TGAGGTAGTTTATAAAGCTGCGA Adult specific Poole et al. (2014)
bma-miR-5364 CGAGGTATTGTTTATTGGCTGA Adult specific Poole et al. (2014)
bma-miR-236-1 TAATACTGTCAGGTAATGACGAT Adult specific Poole et al. (2014)
bma-miR-71 21nt TGAAAGACATGGGTAGTGAGA mf specific Poole et al. (2014)
ov-miR-71 23nt TGAAAGACATGGGTAGTGAGACG Found in human serum Quintana et al. (2015)
ov-miR-71 22nt TGAAAGACATGGGTAGTGAGAC Found in human serum Quintana et al. (2015)
ls-miR-86 TAAGTGAATGCTTTGCCACAGTCT Found in mouse serum Buck et al. (2014)
ls-miR-263 AATGGCACTAGATGAATTCACGG Found in mouse serum Buck et al. (2014)
ls-miR-100a/ov-miR-100a TACCCGTAGCTCCGAATATGTGT Found in mouse and human serum Buck et al. (2014); Quintana et al. (2015)
ls-miR-100b/ov-miR-100d AACCCGTAGTTTCGAACATGTGT Found in mouse and human serum Buck et al. (2014); Quintana et al. (2015)
ls-miR-100c AACCCGTAGAATTGAAATCGTGT Found in mouse serum Buck et al. (2014)
ov-miR-87-3p GTGAGCAAAGTTTCAGGTGTTC Found in human serum Quintana et al. (2015)
ls-bantam-a/ov-bantam-a TGAGATCATTGTGAAAGCTATT Found in mouse and human serum Buck et al. (2014; Quintana et al. (2015)
ls-bantam-b TGAGATCACGTTACATCCGCCT Found in mouse serum Buck et al. (2014)
ls-bantam-c TGAGATCATGCCACATCCGTCT Found in mouse serum Buck et al. (2014)






UnsiSp6 cDNA synthesis spike-in
cel-miR-39-3p cDNA synthesis spike-in
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Poole et al. 2014; Quintana et al. 2015). A number of these
miRNAs were found upon small RNA sequencing of serum
samples from O. volvulus-infected individuals, while others
were detected for other filarial species and have homologous
sequence inO. volvulus (Table 2). For each of these miRNAs,
a PCR primer set was designed (Exiqon, Vedbaek, Denmark)
and used to analyze a set of plasma samples collected from 23
nodule-positive individuals and 6 non-endemic controls living
in Ghana.
Results of internal and external controls were similar for
all samples (Fig. 2a). Of the 17 parasitic miRNAs analyzed,
only 5 appeared to be found positive in a number of samples:
bma-miR-236-1, bma-miR-71, ov-miR-71-23nt, ov-miR-
100d, and ov-miR-87-3p (Fig. 2b). Since it is known that less
diluted cDNA is well tolerated in the miRCURY LNA
Universal RT microRNA PCR system, we investigated
whether sensitivity of the qRT-PCR assays could be in-
creased by using less diluted cDNA (Egidi et al. 2015; Li
et al. 2014). Therefore, sampleswere reanalyzed for the three
miR-71 variants, ov-miR-100d, and ov-miR-87-3p, using 8-
fold diluted cDNA (Fig. 2c). Most samples now appeared to
showpositive signals for bma-miR-71, ov-miR-71-22nt, and
ov-miR-71-23nt. For ov-miR-87-3p, 2 samples turned out to
be positive, one more than using more diluted cDNA. Of the
two positive results found for ov-miR-100d, only one could
be confirmed. In order to confirm the specificity of the sig-
nals observed for the miR-71 variants and ov-miR-87-3p,
melting curves obtained with the synthetic miRNAs and all
clinical samples that had signal in qRT-PCR (also those with
Cq above the cutoff) were compared (Fig. 2d). Even though
both sample sets were analyzed using the same qPCR condi-
tions, a highly significant difference inTmvalueswas appre-
ciated (P < 0.001), indicating that the signals obtained for
these miRNAs in the clinical samples are not specific and
are presumably caused by non-specific amplification of one
or more other miRNAs present in the samples. Results are
shown for cDNA that was diluted 8-fold, but melting tem-
peratures obtained using 50-fold diluted cDNA showed
similar differences in Tm values (data not shown). In con-
trast, Tm values obtained for the human reference miRNAs
did perfectly match between the synthetic miRNAs and clin-
ical samples (P > 0.05).
Determination of serum levels of parasitic miRNAs
in samples from microfilaridermic subjects
We also determined the levels of these miRNAs in serum
from 20 individuals with high microfilarial load (>25 mf/
mg) and 6 healthy controls. All individual results of internal
and external controls are graphically summarized in Fig. 3a.
Based on the different spike-ins, six samples from infected
individuals out of 20 were excluded from further analysis as
they showed a markedly poorer extraction efficiency and/or
cDNA synthesis efficiency and were identified as outliers
(samples MC260, MC211, MC224, MC234, MC253, and
MC215). These samples also had lower levels of human
miRNAs, confirming their poor extraction and/or cDNA
synthesis efficiency. All samples from healthy volunteers
had good extraction and cDNA synthesis efficiency, as well
as relatively high expression of human miRNAs. When
comparing the results of the human miRNAs in these serum
samples with the plasma samples described previously, a
substantial difference is observed. This is first of all attrib-
uted to the fact that lower input volumes have been used
during extraction of these serum samples (Table 3).
Secondly, it is known that plasma and serum miRNA levels
do not fully correlate and plasma levels tend to be slightly
higher (according to the guidelines for the miRCURY LNA
Universal RT microRNA PCR system).
Results of the parasitic miRNAs of all samples that
passed previous selection are presented in Fig. 3b. Only 4
of the 17 parasitic miRNAs investigated showed a positive
signal in one of the samples analyzed (ov-bantam-a, ov-
miR-71-23nt, ov-miR-100d, and ov-miR71-22nt). For the
other parasitic miRNAs, signals were detected, but signals
observed were very low and, in many cases, were present
both in samples from infected individuals and healthy
volunteers.
Discussion
The discovery of miRNAs being secreted by parasites into the
circulation of the host has resulted in several speculations
about their diagnostic utility. Whereas for blood-borne para-
sites, such as Lo. loa, D. immitis, and Li. sigmodontis, large
number of different miRNAs was detected in the host circu-
lation, initial studies on plasma or serum from O. volvulus-
infected individuals only revealed a very small number of
parasite-derived miRNAs (Buck et al. 2014; Quintana et al.
2015; Tritten et al. 2014a; Tritten et al. 2014b). Also, the
Fig. 1 Standard curves of six synthetic miRNAs
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amount of these miRNAs was very low, already indicating a
sensitivity challenge for its diagnostic utility. This sensitivity
challenge becomes even more important when looking to the
possibility of using parasite-derived miRNAs for treatment
monitoring, as a sufficiently broad dynamic range is required
for this application.
We have used standard miRNA extraction and RT-qPCR
technology to detect 17 of these previously identified
miRNAs in plasma or serum from O. volvulus-infected indi-
viduals. A first sample set was collected from nodule-positive
individuals in Ghana with very low or no microfilaria detected
in the skin snip, while a second sample set was obtained from
nodule-positive individuals in Cameroon with high microfi-
larial load. When both datasets are combined, only seven
miRNAs appeared to result in a detectable signal in qPCR:
bma-miR-236-1, bma-miR-71, ov-miR71-22nt, ov-miR-71-
23nt, ov-miR-100d, ov-bantam-a, and ov-miR-87-3p.
Interestingly, all except bma-miR-236-1 were previously also
detected in serum from infected individuals (Quintana et al.
2015). For four of these parasitic miRNAs (three miR-71 var-
iants and ov-miR-87-3p), calibration curves were prepared
using synthetic miRNAs and Tm was determined both for
these synthetic miRNAs and the clinical samples. For all four
parasitic miRNAs, Tm differed significantly between the clin-
ical samples and the synthetic miRNAs, while a similar exer-
cise for the human reference miRNAs showed no difference.
This observation strongly suggests that the signals observed
for these parasitic miRNAs are caused by non-specific ampli-
fication and are not reflecting true positive signals.
Furthermore, as was also observed previously, plasma levels
Fig. 2 miRNA analysis in plasma from nodule-positive individuals
(closed circles) and non-endemic controls (closed squares) from Ghana.
a Internal and external control results. b Results of 17 parasitic miRNAs.
cResult of five selectedO. volvulusmiRNAs, using less diluted cDNA. d
Tm determination of miRNA amplicons obtained with clinical samples
(closed circles) and synthetic miRNAs (open circles)
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of the other miRNAs are extremely low with Cq values just
below the cutoff. Also, these miRNAs were detected in only
very few samples and are not universally present in all or most
infected individuals, which is an essential property for use as a
diagnostic marker.
The discrepancy in Tm between synthetic miRNAs and
clinical samples highlights the importance of using synthetic
miRNAs to confirm the specificity of the RT-qPCR signals
obtained. Whereas in small RNA sequencing technologies,
the sequence of every single miRNA molecule is determined,
qPCR-based detection methodologies are sensitive to non-
specific detection (Dellett and Simpson 2016). Since
miRNAs are usually only 18–22 nucleotides in length, spec-
ificity remains one of the key issues when developing RT-
qPCR assays to measure microRNAs for molecular diagnosis
(Bartel 2004; Dellett and Simpson 2016). Especially when
analyzing low abundant miRNAs in a background of millions
of copies of other miRNAs (and other small RNAs), one needs
to confirm the specificity of the assays before drawing any
conclusion.
Importantly, our study does not completely exclude the
applicability of plasma-derived parasitic miRNAs as a tool
to detect the presence of parasite using minimally invasive
sampling procedures. Our work indicates that sensitive meth-
odologies will be required that also demonstrate high specific-
ity. As this study was limited to only one qPCR-based tech-
nology using commercially available reagents, further optimi-
zation of the qPCR assays or evaluation of other detection
platforms, such as stem-loop RT-PCR, might offer some im-
provements (Chen et al. 2005; Mestdagh et al. 2014). It re-
mains, however, questionable whether detection of parasitic
miRNAs with sufficient diagnostic power will be feasible,
even after elaborate assay optimization. The most obvious
path forward to increase sensitivity might be to use higher
volumes of plasma for miRNA extraction. Standard miRNA
extraction kits, however, are not designed to use higher vol-
umes, and this approach would therefore have limited feasi-
bility in practice. Alternatively, a preamplification step might
be introduced as this has been shown before to boost sensitiv-
ity (Tan et al. 2015). One other interesting approach might be
the use of a precursory isolation of parasite-specific exosomes.
It was shown for the helminth parasites Heligmosomoides
polygyrus and B. malayi that these parasites secrete miRNA-
containing vesicles, possibly involved in modulation of the
host’s immune response (Buck et al. 2014; Zamanian et al.
2015; Zheng et al. 2016). Isolation of total exosomes or even
of parasite-specific exosomes could result in an enrichment of
parasitic miRNAs, thereby reducing the background of non-
parasite-derived miRNAs during analysis. The same work,
however, also indicated that exosomes and associated RNAs
operate locally in the host’s body and that their detection will
depend on the stage and localization of the parasite in the host
(Buck et al. 2014). It is therefore not surprising to observe the
low amounts of parasitic miRNAs in the circulation upon
infection with the skin localized O. volvulus as compared to,
e.g., infection withD. immitis or B. malayi, two parasites with
a blood-borne microfilarial stage (Tritten et al. 2014a).
In conclusion, our data indicate that O. volvulus miRNAs
are not present in circulation in sufficiently high amounts to be
used as a diagnostic marker for infection or treatment moni-
toring using LNA-based RT-qPCR analysis.
Cq, Quantification cycle; mf, microfilaria; miRNA,
microRNA; O. volvulus, Onchocerca volvulus; qPCR, quan-
titative PCR; RT, reverse transcriptase
Fig. 3 miRNA analysis in serum from individuals with highmicrofilarial
load from Cameroon (closed circles) and healthy controls from Southern
Africa (closed squares). a Internal and external control results. Samples
that showed reduced extraction and/or cDNA synthesis are indicated by
triangles. b Results of 17 parasitic miRNAs
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